Details of the Drug

General Information of Drug (ID: DM0659E)

Drug Name
Cannabidiol
Synonyms
cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
Indication
Disease Entry ICD 11 Status REF
Dravet syndrome 8A61.11 Approved [1]
LennoxGastaut syndrome 8A62.1 Approved [1]
Infantile spasm 8A62.0 Phase 3 [2]
Epilepsy 8A60-8A68 Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 314.5
Logarithm of the Partition Coefficient (xlogp) 6.5
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 13.55 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.44 hours (CBD component of sublingual Sativex), and 1.81 hours (buccal Sativex) [3]
Metabolism
The drug is metabolized via the liver []
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.69 L/kg [3]
Chemical Identifiers
Formula
C21H30O2
IUPAC Name
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Canonical SMILES
CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O
InChI
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
Cross-matching ID
PubChem CID
644019
ChEBI ID
CHEBI:69478
CAS Number
13956-29-1
DrugBank ID
DB09061
TTD ID
D0O1UZ
VARIDT ID
DR00249
INTEDE ID
DR0265
ACDINA ID
D00909
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor (CB) TT94IAG NOUNIPROTAC Binder [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCG1) OTSBQR6D PLCG1_HUMAN Gene/Protein Processing [8]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Gene/Protein Processing [9]
26S proteasome regulatory subunit 6B (PSMC4) OTS3XN41 PRS6B_HUMAN Gene/Protein Processing [10]
4-trimethylaminobutyraldehyde dehydrogenase (ALDH9A1) OTNWHUJ1 AL9A1_HUMAN Gene/Protein Processing [8]
5' exonuclease Apollo (DCLRE1B) OT2LFW7A DCR1B_HUMAN Gene/Protein Processing [9]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Gene/Protein Processing [11]
5'-nucleotidase domain-containing protein 2 (NT5DC2) OTPDRGGN NT5D2_HUMAN Gene/Protein Processing [12]
5,6-dihydroxyindole-2-carboxylic acid oxidase OTRK49R4 TYRP1_HUMAN Gene/Protein Processing [13]
5-azacytidine-induced protein 2 (AZI2) OT61Q7Q8 AZI2_HUMAN Gene/Protein Processing [14]
5-hydroxytryptamine receptor 1D (HTR1D) OTLS74AF 5HT1D_HUMAN Gene/Protein Processing [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cannabidiol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Tagraxofusp. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Moderate Increased metabolism of Cannabidiol caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Gilteritinib DMTI0ZO Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Gilteritinib. Acute myeloid leukaemia [2A60] [16]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Inotersen. Amyloidosis [5D00] [16]
Troleandomycin DMUZNIG Minor Decreased metabolism of Cannabidiol caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [16]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Cannabidiol and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [17]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and LY2835219. Breast cancer [2C60-2C6Y] [16]
Tucatinib DMBESUA Moderate Decreased metabolism of Cannabidiol caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [16]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Intedanib. Colorectal cancer [2B91] [16]
MK-8228 DMOB58Q Minor Decreased metabolism of Cannabidiol caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [16]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Cannabidiol and Esketamine. Depression [6A70-6A7Z] [15]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [16]
Stiripentol DMMSDOY Minor Decreased metabolism of Cannabidiol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [16]
Tazemetostat DMWP1BH Moderate Increased metabolism of Cannabidiol caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [19]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [16]
Cobicistat DM6L4H2 Minor Decreased metabolism of Cannabidiol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [16]
Berotralstat DMWA2DZ Minor Decreased metabolism of Cannabidiol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [16]
Ceritinib DMB920Z Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Ceritinib. Lung cancer [2C25] [16]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Alectinib. Lung cancer [2C25] [16]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Pralsetinib. Lung cancer [2C25] [16]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Selpercatinib. Lung cancer [2C25] [16]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [16]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and IPI-145. Mature B-cell leukaemia [2A82] [16]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Arry-162. Melanoma [2C30] [16]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Cannabidiol and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [20]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Cannabidiol and Lasmiditan. Migraine [8A80] [21]
Siponimod DM2R86O Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Siponimod. Multiple sclerosis [8A40] [16]
Fedratinib DM4ZBK6 Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Fedratinib. Myeloproliferative neoplasm [2A20] [16]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Entrectinib. Non-small cell lung cancer [2C25] [16]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Sarilumab. Rheumatoid arthritis [FA20] [16]
Voxelotor DMCS6M5 Minor Decreased metabolism of Cannabidiol caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [16]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [16]
LEE011 DMMX75K Minor Decreased metabolism of Cannabidiol caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Fostamatinib. Thrombocytopenia [3B64] [16]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Lenvatinib. Thyroid cancer [2D10] [16]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Cannabidiol and Elagolix. Uterine fibroid [2E86] [16]
⏷ Show the Full List of 39 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Levomenthol E00248 16666 Flavoring agent
Sucralose E00370 71485 Flavoring agent
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydrogenated polyoxyl 40 castor oil E00662 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Potassium sorbate E00566 23676745 Antimicrobial preservative
Water E00035 962 Solvent
Glyceryl oleate E00618 Not Available Other agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cannabidiol 1.938 g/100 ml spray 1.938 g/100 ml Spray Oral
Cannabidiol 100 mg/ml solution 100 mg/ml Solution Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106.
5 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
6 Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
7 Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
8 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
9 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
10 Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
11 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
12 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
13 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
14 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
19 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
20 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
21 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.